Abstract: Gallbladder cancer (GBC) is highly malignant and is associated with a poor prognosis. Gemcitabine and platinum, gemcitabine and S-1, or a combination of the three drugs are often used in the first-line chemotherapy of GBC. Second-line chemotherapy, such as 5-fluorouracil and oxaliplatin, is also used. Immunotherapy includes vaccination, adoptive immunotherapy, and checkpoint inhibition. Pembrolizumab and nivolumab targeting programmed death-1, or in combination with chemotherapy, have shown promising therapeutic efficacy. Combined immunotherapy, such as a combination with targeting cytotoxic T-lymphocyte antigen 4 drugs, has also been applied in clinical practice. Targeted therapy which targets human epidermal growth factor receptor 2, epidermal growth factor receptor, and vascular endothelial growth factor receptor is used for advanced GBC alone or in combination with chemotherapy. Individual precision therapy for GBC will be the focus of future studies. Large-scale randomized controlled studies on GBC are expected.